Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Net Cash Flow: 2009-2025

Historic Net Cash Flow for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $2.8 million.

  • Lifecore Biomedical's Net Cash Flow fell 47.15% to $2.8 million in Q2 2025 from the same period last year, while for May 2025 it was -$197,000, marking a year-over-year increase of 98.15%. This contributed to the annual value of -$197,000 for FY2025, which is 98.15% up from last year.
  • Per Lifecore Biomedical's latest filing, its Net Cash Flow stood at $2.8 million for Q2 2025, which was up 170.53% from -$4.0 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Net Cash Flow registered a high of $16.1 million during Q2 2023, and its lowest value of -$10.4 million during Q3 2023.
  • In the last 3 years, Lifecore Biomedical's Net Cash Flow had a median value of -$1.5 million in 2024 and averaged $143,500.
  • As far as peak fluctuations go, Lifecore Biomedical's Net Cash Flow surged by 7,749.76% in 2023, and later slumped by 2,628.38% in 2025.
  • Lifecore Biomedical's Net Cash Flow (Quarterly) stood at -$356,000 in 2021, then soared by 832.58% to $2.6 million in 2022, then tumbled by 307.86% to -$5.4 million in 2023, then soared by 172.59% to $3.9 million in 2024, then slumped by 47.15% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q2 2025, -$4.0 million for Q1 2025, and $3.9 million during Q4 2024.